Business
Baxter Appoints Andrew Hider Chief Executive Officer
DEERFIELD, Ill., July 07, 2025--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent
About this update from Baxter International Inc.
[{"type":"image","alt":"Andrew Hider Appointed Baxter's Next CEO","displaySize":"","headline":null,"caption":"Andrew Hider Appointed Baxter's Next CEO","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/ed2e5de697be58d779312658868edfe0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QFeJjBLBOD9OY_kW4FdMcg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ed2e5de697be58d779312658868edfe0","width":480,"height":480}},"lazy":false},{"type":"text","content":"DEERFIELD, Ill., July 07, 2025--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board.","length":544,"tagName":"p"},{"type":"text","content":"Since 2017, Mr. Hider has served as CEO of ATS Corporation (TSX and NYSE: ATS), an industry-leading provider of advanced automation solutions for companies in the life sciences, food and beverage, transportation, consumer products, and energy industries. Under Mr. Hider’s leadership, ATS has optimized its portfolio by strategically shifting investments towards higher-growth end markets, while also delivering meaningful margin improvement. Over a five-year period ending with the company's last fiscal year, ATS’s adjusted revenues have nearly doubled, representing a low-to-mid teens CAGR (compound annual growth rate) and similar adjusted EBITDA CAGR over the same period1. Since Mr. Hider’s appointment in 2017, ATS’s stock price has more than tripled on the TSX, significantly outperforming major indices over the same period.","length":837,"tagName":"p"},{"type":"text","content":"Like Baxter, ATS is a global, diversified, customer-centric company with a broad scale and range of capabilities. As of 2025, ATS operates 65+ manufacturing facilities globally. ATS’s largest end-market is now its life sciences segment where its teams play a critical role enabling the d...